Literature DB >> 2037026

Experimental autoimmune anterior uveitis (EAAU), a new form of experimental uveitis. I. Induction by a detergent-insoluble, intrinsic protein fraction of the retinal pigment epithelium.

R M Broekhuyse1, E D Kuhlmann, H J Winkens, A H Van Vugt.   

Abstract

The uveitogenicity of several protein fractions of the bovine retinal pigment epithelium (RPE) was studied in Lewis rats, and a major pathogenic fraction was selected. Fresh RPE cells were carefully isolated and purified in order to minimize the presence of rod outer segments (ROS). The buffer-insoluble part of the cells was extracted by Triton X-100. Most uveitogenicity was found in the Triton-insoluble pigment and cytoskeleton-containing fraction of RPE (RPE-TI). The S-antigen and opsin contents of RPE-TI were too low to induce an inflammatory response, while transducin, IRBP and cGMP-phosphodiesterase were absent. Hence, a hitherto unknown uveitogenic RPE protein, called PEP-X, evoked the pathogenic response. A typical dose-dependent experimental autoimmune anterior uveitis (EAAU) developed when the rats were immunized with RPE-TI. Initially, mononuclear cells infiltrated the anterior segment. In subsequent severe stages polymorphonuclear cells predominated in the anterior chamber. EAAU differed in particular from the known forms of EAU induced by photoreceptor proteins in that the inflammation remained exclusively anterior and the photoreceptor cells and the pineal gland were not affected. In immunized rats the immune responses to ROS proteins were very low. In contrast, there were consistently high cellular and humoral immune responses to RPE-TI. As in experimental autoimmune (uveo)retinitis (EAU), the development of EAAU could be inhibited by cyclosporin treatment indicating T-cell-dependency. A combination of histopathological, immunological and biochemical results indicates that PEP-X is an intrinsic RPE protein that is highly pathogenic. In view of its characteristics, EAAU may be a valuable model for human acute anterior uveitis, the most prevalent form of uveitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037026     DOI: 10.1016/0014-4835(91)90044-f

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  23 in total

Review 1.  Anterior uveitis: clinical and research perspectives.

Authors:  J T Rosenbaum; T M Martin; S R Planck
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Apoptosis of CD4+ T cells occurs in experimental autoimmune anterior uveitis (EAAU).

Authors:  H G Yu; H Chung; W J Lee
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  Tolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ T-regulatory cells.

Authors:  Bharati Matta; Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

Review 4.  Immunopathology of uveitis.

Authors:  C C Chan; Q Li
Journal:  Br J Ophthalmol       Date:  1998-01       Impact factor: 4.638

5.  Experimental melanin-induced uveitis in the Fischer 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate.

Authors:  J R Smith; P H Hart; C R Parish; S D Standfield; D J Coster; K A Williams
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

6.  Anti-inflammatory effects of specific cyclooxygenase 2,5-lipoxygenase, and inducible nitric oxide synthase inhibitors on experimental autoimmune anterior uveitis (EAAU).

Authors:  Nalini S Bora; Jeong-Hyeon Sohn; Puran S Bora; Henry J Kaplan; Prasad Kulkarni
Journal:  Ocul Immunol Inflamm       Date:  2005 Apr-Jun       Impact factor: 3.070

7.  The complement system plays a critical role in the development of experimental autoimmune anterior uveitis.

Authors:  Purushottam Jha; Jeong-Hyeon Sohn; Qin Xu; Hiroki Nishihori; Yali Wang; Saori Nishihori; Balasubramanian Manickam; Henry J Kaplan; Puran S Bora; Nalini S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

Review 8.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

9.  A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor.

Authors:  Joonhong Sohn; Ju Byung Chae; Sun Young Lee; Soo-Youl Kim; June-Gone Kim
Journal:  Korean J Ophthalmol       Date:  2010-02-05

10.  Antigen-specific tolerance inhibits autoimmune uveitis in pre-sensitized animals by deletion and CD4+CD25+ T-regulatory cells.

Authors:  Bharati Matta; Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Immunol Cell Biol       Date:  2009-11-03       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.